Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

Fig. 4

Predicted total mutation load (PTML) correlates with immunotherapy outcomes in lung adenocarcinoma. Lung adenocarcinoma patients with a low PTML (≤ 100) treated with pembrolizumab fail to obtain a partial tumor response (a), fail to obtain a durable clinical response (b), and have a markedly lower progression-free survival (PFS) compared to patients with a high PTML (c) (PFS curve: low PTML = red line, high PTML = black line)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us